Ipsen: Appointment of Gérard Picotas Vice President, Global Regulatory Affairs

Regulatory News: Ipsen (Paris:IPN) today announced the appointment, of Gérard

Picot as Vice-President, Global Regulatory Affairs. He reports to Stéphane

Thiroloix, Executive Vice President, Corporate Development. This

appointment is within the context of the retirement of Mr William Jones. His main mission will be to enhance the regulatory position of Ipsen

its products and those of its partners worldwide, thanks to the strong

network of teams based in Paris (France), Slough (United Kingdom), and

Boston (United States). Gérard Picot brings

along a history of solid delivery in the regulatory arena, a rich

track-record of staff development, a strong strategic thinking ability

and a proven drive to partner through change. Gérard Picot, 55, holds a Doctorate in

Pharmaceutical Sciences and an MS in Drug Law from the University of

Paris. He started his career in 1982 within Merck, Sharpe & Dohme´s

US Regulatory Affairs Group. He then took in 1987 responsibility for

Drug Development at Laboratoires Fournier, before joining Bristol-Myers

Squibb´s Regulatory Affairs group in 1990

where he was most recently VP, Global Regulatory Sciences for Europe

Middle-East and Africa. Since 1991, Gérard

has been a member or permanent guest of EFPIA´s

(European Federation of Pharmaceutical Industry Associations)

Scientific, Technical and Regulatory Policy Committee. About Ipsen Ipsen is an innovation-driven international specialty pharmaceutical

group with over 20 products on the market and a total worldwide staff of

nearly 4,000. Its development strategy is based on a combination of

specialty products, which are growth drivers, in targeted therapeutic

areas (oncology, endocrinology and neuromuscular disorders), and primary

care products which contribute significantly to its research financing.

The location of its four Research & Development centres (Paris, Boston

Barcelona, London) and its peptide and protein engineering platform give

the Group a competitive edge in gaining access to leading university

research teams and highly qualified personnel. More than 700 people in

R&D are dedicated to the discovery and development of innovative drugs

for patient care.This strategy is also supported by an active policy of

partnerships. In 2007, Research and Development expenditure was about ?185

million, in excess of 20% of consolidated sales, which amounted to ?920.5

million while total revenues amounted to ?993.8

million. Ipsen´s shares are traded on Segment

A of Eurolist by EuronextTM (stock code: IPN

ISIN code: FR0010259150). Ipsen´s shares are

eligible to the "Service de Règlement

Différé" ("SRD") and the

Group is part of the SBF 120 index. For more information on Ipsen, visit

our website at www.ipsen.com. Ipsen Forward-looking statements The forward-looking statements and targets contained herein are based on

Ipsen´s management´s current views and assumptions. Such statements

involve known and unknown risks and uncertainties that may cause actual

results, performance or events to differ materially from those

anticipated herein. The targets contained herein were prepared without

taking into account external growth assumptions, which may alter the

parameters. These targets are based on data and assumptions regarded as

reasonable by the Group and depend on conditions or facts likely to

happen in the future, and not exclusively on historical data. Actual

results may depart significantly from the targets given the occurrence

of certain risks and uncertainties. The Group does not commit nor gives

any guarantee that it will meet the targets mentioned above. Moreover

the Research and Development process involves several stages at each of

which there is a substantial risk that the Group will fail to achieve

its objectives and be forced to abandon its efforts in respect of a

product in which it has invested significant sums. Therefore, the Group

cannot be certain that favourable results obtained during pre-clinical

trials will be confirmed subsequently during clinical trials, or that

the results of clinical trials will be sufficient to demonstrate the

safe and effective nature of the product concerned. Moreover, the

targets described in this document were prepared without taking into

account external growth assumptions, which may alter these parameters.

These targets are based on data and assumptions regarded as reasonable

by the Group. These targets depend on conditions or facts likely to

happen in the future, and not exclusively on historical data. Actual

results may depart significantly from these targets given the occurrence

of certain risks and uncertainties. The Group does not commit nor gives

any guarantee that it will meet the targets mentioned above. Ipsen

expressly disclaims any obligation or undertaking to update or revise

any forward looking statements, targets or estimates contained in this

press release to reflect any change in events, conditions, assumptions

or circumstances on which any such statements are based, unless so

required by applicable law. Ipsen´s business is subject to the risk

factors outlined in its information documents filed with the French Autorité des Marchés Financiers.